Love Employee
- Eisai (OTCPK:ESALF) has received the rights back to antibody drug conjugate farletuzumab ecteribulin (FZEC) after Bristol-Myers Squibb (NYSE:BMY) ended a strategic collaboration on the candidate.
- The Japanese pharma said it will accelerate development of the asset on its own. Eisai (ESAIY) has an ongoing phase 1 study in solid tumors, while Bristol is currently conducting two phase 2 studies, one in ovarian, peritoneal and fallopian tube cancers, and the other in non-small cell lung cancer.
- FZEC is a combination of farletuzumab, a humanized IgG1 monoclonal antibody that binds to FRα, a protein seen in some solid tumors, and anticancer agent eribulin.